Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer

BACKGROUND: For many patients with resected epidermal growth factor receptor mutation-positive (EGFRm) non-small cell lung cancer (NSCLC), current standard of care (SoC) is adjuvant chemotherapy; however, disease recurrence remains high. Based on positive results from ADAURA (NCT02511106), adjuvant...

Descripción completa

Detalles Bibliográficos
Autores principales: Verhoek, Andre, Cheema, Parneet, Melosky, Barbara, Samson, Benoit, Shepherd, Frances A., de Marinis, Filippo, John, Thomas, Wu, Yi-Long, Heeg, Bart, Van Dalfsen, Nadia, Bracke, Benjamin, Miranda, Miguel, Shaw, Simon, Moldaver, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169948/
https://www.ncbi.nlm.nih.gov/pubmed/36811822
http://dx.doi.org/10.1007/s41669-023-00396-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169948/
https://www.ncbi.nlm.nih.gov/pubmed/36811822
http://dx.doi.org/10.1007/s41669-023-00396-0

Ejemplares similares